Operaciones Ionis Pharmaceuticals, Inc. - IONS CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | 0.03 | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024068% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.001846% | ||||||||
Horario tarifa nocturna | 21:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | USD | ||||||||
Margen | 20% | ||||||||
Mercado de valores | United States of America | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
Cierre previo* | 33.67 |
Abrir* | 33.59 |
Cambio de 1 año* | -8.27% |
Rango del día* | 33.35 - 34.31 |
Rango de 52 semanas | 31.46-48.82 |
Volumen medio (10 días) | 1.13M |
Volumen medio (3 meses) | 19.92M |
Capitalización de mercado | 4.82B |
Ratio P/E | -100.00K |
Acciones en circulación | 142.95M |
Ingresos | 587.37M |
EPS | -1.90 |
Dividendo (Rendimiento %) | N/A |
Beta | 0.54 |
Próxima fecha de resultados | May 2, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
Mar 28, 2023 | 34.27 | 1.69 | 5.19% | 32.58 | 34.33 | 32.58 |
Mar 27, 2023 | 33.67 | -0.24 | -0.71% | 33.91 | 34.30 | 33.46 |
Mar 24, 2023 | 33.91 | 0.61 | 1.83% | 33.30 | 34.13 | 32.65 |
Mar 23, 2023 | 33.61 | -1.58 | -4.49% | 35.19 | 35.41 | 33.28 |
Mar 22, 2023 | 35.16 | 0.14 | 0.40% | 35.02 | 35.57 | 34.55 |
Mar 21, 2023 | 35.47 | 0.53 | 1.52% | 34.94 | 35.75 | 34.67 |
Mar 20, 2023 | 35.45 | -0.31 | -0.87% | 35.76 | 36.04 | 35.03 |
Mar 17, 2023 | 35.04 | 0.77 | 2.25% | 34.27 | 35.20 | 33.70 |
Mar 16, 2023 | 34.86 | 1.50 | 4.50% | 33.36 | 35.00 | 33.36 |
Mar 15, 2023 | 34.15 | 0.99 | 2.99% | 33.16 | 34.18 | 32.63 |
Mar 14, 2023 | 33.74 | 0.43 | 1.29% | 33.31 | 33.88 | 32.39 |
Mar 13, 2023 | 33.50 | 0.15 | 0.45% | 33.35 | 34.65 | 33.35 |
Mar 10, 2023 | 33.91 | 0.05 | 0.15% | 33.86 | 34.75 | 33.52 |
Mar 9, 2023 | 34.62 | -0.80 | -2.26% | 35.42 | 35.72 | 34.28 |
Mar 8, 2023 | 35.62 | 0.12 | 0.34% | 35.50 | 35.83 | 35.15 |
Mar 7, 2023 | 35.65 | -0.22 | -0.61% | 35.87 | 36.14 | 35.49 |
Mar 6, 2023 | 36.12 | -0.10 | -0.28% | 36.22 | 36.63 | 35.81 |
Mar 3, 2023 | 36.45 | 0.91 | 2.56% | 35.54 | 36.71 | 35.01 |
Mar 2, 2023 | 35.66 | 0.39 | 1.11% | 35.27 | 35.84 | 35.07 |
Mar 1, 2023 | 35.89 | 0.28 | 0.79% | 35.61 | 36.31 | 34.93 |
Ionis Pharmaceuticals, Inc. Events
Hora (UTC) (UTC) | País | Evento |
---|---|---|
No events scheduled |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Ingresos totales | 587.367 | 810.456 | 729.264 | 1122.6 | 599.674 |
Ingresos | 587.367 | 810.456 | 729.264 | 1122.6 | 599.674 |
Coste de los ingresos, total | 14.116 | 10.842 | 11.947 | 4.384 | 1.82 |
Beneficio bruto | 573.251 | 799.614 | 717.317 | 1118.21 | 597.854 |
Gastos totales de explotación | 997.558 | 849.269 | 901.346 | 822.912 | 661.046 |
Gastos de venta/general/administración Gastos, total | 150.295 | 170.947 | 332.222 | 286.644 | 244.622 |
Investigación y desarrollo | 833.147 | 634.953 | 526.877 | 465.688 | 414.604 |
Gastos (ingresos) extraordinarios | 32.527 | 30.3 | 66.196 | 0 | |
Ingresos de explotación | -410.191 | -38.813 | -172.082 | 299.687 | -61.372 |
Ingresos por intereses (gastos), netos No operativos | 9.876 | 10.798 | 37.592 | 39.765 | -14.602 |
Otros, netos | -7.274 | -1.133 | -0.062 | -0.686 | -0.182 |
Ingresos netos antes de impuestos | -257.985 | -29.148 | -134.552 | 338.766 | -76.156 |
Ingresos netos después de impuestos | -269.722 | -28.597 | -479.743 | 287.259 | -117.115 |
Intereses menores | 0 | 0 | 35.48 | -9.116 | 58.756 |
Beneficio neto antes de partidas extra. Elementos | -269.722 | -28.597 | -444.263 | 278.143 | -58.359 |
Ingresos netos | -269.722 | -28.597 | -444.263 | 278.143 | 273.741 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -269.722 | -28.597 | -444.263 | 278.143 | -58.359 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -269.722 | -28.597 | -444.263 | 278.143 | 273.741 |
Ajuste por dilución | 0 | ||||
Beneficio neto diluido | -269.722 | -28.597 | -444.263 | 278.143 | 273.741 |
Promedio ponderado de acciones diluidas | 141.848 | 141.021 | 139.612 | 153.164 | 134.056 |
BPA diluido sin partidas extraordinarias | -1.90149 | -0.20279 | -3.18213 | 1.81598 | -0.43533 |
BPA normalizado diluido | -2.58703 | -0.05286 | -3.04106 | 2.18246 | -0.43533 |
Total de partidas extraordinarias | 332.1 | ||||
Gain (Loss) on Sale of Assets | 149.604 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Ingresos totales | 151.889 | 159.767 | 133.791 | 141.919 | 440.006 |
Ingresos | 151.889 | 159.767 | 133.791 | 141.919 | 440.006 |
Coste de los ingresos, total | 3.686 | 1.515 | 4.745 | 4.17 | 2.226 |
Beneficio bruto | 148.203 | 158.252 | 129.046 | 137.749 | 437.78 |
Gastos totales de explotación | 359.908 | 218.921 | 219.305 | 199.423 | 219.401 |
Gastos de venta/general/administración Gastos, total | 47.95 | 34.416 | 33.802 | 34.127 | 37.6 |
Investigación y desarrollo | 308.272 | 182.99 | 180.758 | 161.126 | 179.575 |
Ingresos de explotación | -208.019 | -59.154 | -85.514 | -57.504 | 220.605 |
Ingresos por intereses (gastos), netos No operativos | 13.436 | 7.732 | -5.064 | -6.754 | 4.788 |
Otros, netos | 0.649 | 4.713 | -12.297 | 0.187 | -0.477 |
Ingresos netos antes de impuestos | -44.33 | -46.709 | -102.875 | -64.071 | 224.916 |
Ingresos netos después de impuestos | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Intereses menores | 0 | 0 | |||
Beneficio neto antes de partidas extra. Elementos | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Ingresos netos | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Beneficio neto diluido | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Promedio ponderado de acciones diluidas | 142.046 | 141.95 | 141.794 | 141.599 | 141.21 |
BPA diluido sin partidas extraordinarias | -0.36911 | -0.33105 | -0.74146 | -0.46021 | 1.59063 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
BPA normalizado diluido | -1.05369 | -0.33105 | -0.74146 | -0.46021 | 1.59063 |
Gastos (ingresos) extraordinarios | 0 | ||||
Gain (Loss) on Sale of Assets | 149.604 |
- Anual
- Trimestral
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Activo Corriente | 2345.05 | 2130.71 | 2720.6 | 2207.89 | 1168.73 |
Efectivo e inversiones a corto plazo | 2114.97 | 1892.38 | 2499.54 | 2084.07 | 1022.72 |
Efectivo y Equivalentes | 869.191 | 397.664 | 683.287 | 278.82 | 129.63 |
Inversiones a corto plazo | 1245.78 | 1494.71 | 1816.26 | 1805.25 | 893.085 |
Total deudores, neto | 61.896 | 76.204 | 63.034 | 12.759 | 62.955 |
Accounts Receivable - Trade, Net | 61.896 | 76.204 | 63.034 | 12.759 | 62.955 |
Total Inventory | 24.806 | 21.965 | 18.18 | 8.582 | 9.982 |
Other Current Assets, Total | 143.374 | 140.163 | 139.839 | 102.473 | 73.082 |
Total Assets | 2611.69 | 2389.75 | 3233.11 | 2667.78 | 1322.77 |
Property/Plant/Equipment, Total - Net | 196.069 | 181.077 | 166.251 | 132.16 | 121.907 |
Property/Plant/Equipment, Total - Gross | 298.722 | 240.264 | 193.634 | 209.583 | |
Accumulated Depreciation, Total | -102.653 | -74.013 | -61.474 | -87.676 | |
Intangibles, Net | 29.005 | 27.937 | 25.674 | 24.032 | 22.004 |
Other Long Term Assets, Total | 41.567 | 50.034 | 320.59 | 303.706 | 10.129 |
Total Current Liabilities | 240.55 | 598.898 | 273.005 | 280.294 | 243.612 |
Accounts Payable | 11.904 | 17.199 | 16.067 | 28.66 | 24.886 |
Accrued Expenses | 129.97 | 155.889 | 106.152 | 77.629 | 91.769 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.926 | 316.11 | 13.749 | 1.621 | |
Other Current Liabilities, Total | 97.75 | 109.7 | 150.786 | 160.256 | 125.336 |
Total Liabilities | 1839.95 | 1646.47 | 1762.02 | 1619.7 | 1041.76 |
Total Long Term Debt | 1228.02 | 623.529 | 770.3 | 632.971 | 605.856 |
Long Term Debt | 1228.02 | 623.529 | 770.3 | 632.971 | 605.856 |
Capital Lease Obligations | |||||
Other Liabilities, Total | 371.379 | 424.046 | 505.26 | 567.359 | 108.026 |
Total Equity | 771.737 | 743.282 | 1471.09 | 1048.08 | 281.013 |
Common Stock | 0.141 | 0.14 | 0.14 | 0.138 | 0.125 |
Additional Paid-In Capital | 1964.17 | 1895.52 | 2203.78 | 2047.25 | 1553.68 |
Retained Earnings (Accumulated Deficit) | -1159.9 | -1131.31 | -707.534 | -967.293 | -1241.03 |
Other Equity, Total | -32.668 | -21.071 | -25.29 | -32.016 | -31.759 |
Total Liabilities & Shareholders’ Equity | 2611.69 | 2389.75 | 3233.11 | 2667.78 | 1322.77 |
Total Common Shares Outstanding | 141.21 | 140.366 | 140.34 | 137.929 | 124.976 |
Minority Interest | 213.453 | 139.081 | 84.267 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Activo Corriente | 2253.12 | 2345.05 | 2155.74 | 2238.42 | 1989.42 |
Efectivo e inversiones a corto plazo | 2052.39 | 2114.97 | 1987.1 | 2059.27 | 1819.99 |
Efectivo y Equivalentes | 542.513 | 869.191 | 632.953 | 565.119 | 414.155 |
Inversiones a corto plazo | 1509.88 | 1245.78 | 1354.15 | 1494.15 | 1405.84 |
Total deudores, neto | 26.122 | 61.896 | 9.068 | 24.004 | 23.397 |
Accounts Receivable - Trade, Net | 26.122 | 61.896 | 9.068 | 24.004 | 23.397 |
Total Inventory | 24.032 | 24.806 | 22.93 | 24.099 | 22.199 |
Other Current Assets, Total | 150.577 | 143.374 | 136.643 | 131.045 | 123.827 |
Total Assets | 2519.09 | 2611.69 | 2414.89 | 2497.07 | 2248.55 |
Property/Plant/Equipment, Total - Net | 177.724 | 196.069 | 180.144 | 179.316 | 180.413 |
Intangibles, Net | 29.295 | 29.005 | 30.038 | 29.373 | 28.795 |
Other Long Term Assets, Total | 58.949 | 41.567 | 48.971 | 49.962 | 49.925 |
Total Current Liabilities | 228.45 | 240.55 | 279.778 | 293.825 | 295.105 |
Accounts Payable | 16.125 | 11.904 | 8.357 | 14.658 | 9.506 |
Accrued Expenses | 115.781 | 129.97 | 108.001 | 105.372 | 108.029 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4.206 | 0.926 | 65.045 | 69.848 | 69.504 |
Other Current Liabilities, Total | 92.338 | 97.75 | 98.375 | 103.947 | 108.066 |
Total Liabilities | 1809.52 | 1839.95 | 1884.36 | 1914.4 | 1567.99 |
Total Long Term Debt | 1247.93 | 1228.02 | 1241.69 | 1240.7 | 870.916 |
Long Term Debt | 1247.93 | 1228.02 | 1241.69 | 1240.7 | 870.916 |
Other Liabilities, Total | 333.138 | 371.379 | 362.887 | 379.874 | 401.966 |
Total Equity | 709.574 | 771.737 | 530.536 | 582.674 | 680.564 |
Common Stock | 0.142 | 0.141 | 0.141 | 0.141 | 0.141 |
Additional Paid-In Capital | 1983.08 | 1964.17 | 1942.35 | 1910.38 | 1925.8 |
Retained Earnings (Accumulated Deficit) | -1225.07 | -1159.9 | -1384.52 | -1302.05 | -1221.18 |
Other Equity, Total | -48.578 | -32.668 | -27.437 | -25.796 | -24.203 |
Total Liabilities & Shareholders’ Equity | 2519.09 | 2611.69 | 2414.89 | 2497.07 | 2248.55 |
Total Common Shares Outstanding | 141.753 | 141.21 | 141.184 | 141.022 | 140.924 |
- Anual
- Trimestral
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Ingresos netos/Línea de salida | -28.597 | -479.743 | 287.259 | 214.985 | -10.783 |
Efectivo de actividades de explotación | 30.799 | 35.892 | 345.627 | 602.906 | 174.149 |
Efectivo de actividades de explotación | 15.487 | 13.365 | 12.54 | 10.706 | 6.708 |
Amortization | 2.352 | 2.064 | 1.912 | 1.822 | 1.641 |
Deferred Taxes | 0 | 341.729 | 0.911 | -290.516 | 0 |
Partidas no monetarias | 155.375 | 232.032 | 211.806 | 166.484 | 139.539 |
Intereses pagados en efectivo | 4.778 | 6.247 | 9.87 | 9.592 | 8.035 |
Cambios en el capital circulante | -113.818 | -73.555 | -168.801 | 499.425 | 37.044 |
Efectivo de actividades de inversión | 194.906 | 274.477 | -41.274 | -929.563 | -358.291 |
Gastos de capital | -11.955 | -35.12 | -30.905 | -13.608 | -34.764 |
Otras partidas de flujo de caja de inversión, total | 206.861 | 309.597 | -10.369 | -915.955 | -323.527 |
Efectivo procedente de actividades de financiación | 245.933 | -596.609 | 100.021 | 475.865 | 229.087 |
Elementos de flujo de caja de financiación | -168.954 | -558.097 | -138.354 | 0 | 47.963 |
Emisión (retiro) de acciones, neto | 101.317 | -38.512 | 141.375 | 475.865 | 205.106 |
Emisión (amortización) de deuda, neta | 313.57 | 0 | 97 | 0 | -23.982 |
Variación neta de la tesorería | 471.527 | -285.623 | 404.467 | 149.19 | 44.945 |
Cash Taxes Paid | 0.038 | 25.855 | 9.041 | 0 | |
Efectos del cambio de divisas | -0.111 | 0.617 | 0.093 | -0.018 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -65.165 | -28.597 | -253.21 | -170.744 | -89.869 |
Cash From Operating Activities | -31.65 | 30.799 | -172.888 | -117.314 | -54.662 |
Cash From Operating Activities | 3.701 | 15.487 | 11.665 | 7.951 | 3.917 |
Amortization | 0.592 | 2.352 | 1.74 | 1.137 | 0.544 |
Deferred Taxes | 0 | 0 | 0 | 0 | |
Non-Cash Items | 32.983 | 155.375 | 125.535 | 88.261 | 43.346 |
Cash Taxes Paid | 0.002 | 0.038 | 0.003 | 0.002 | |
Cash Interest Paid | 0.594 | 4.778 | 3.527 | 2.866 | 0.594 |
Changes in Working Capital | -3.761 | -113.818 | -58.618 | -43.919 | -12.6 |
Cash From Investing Activities | -287.549 | 194.906 | 99.797 | -22.174 | 78.856 |
Capital Expenditures | -2.705 | -11.955 | -9.453 | -6.13 | -1.772 |
Other Investing Cash Flow Items, Total | -284.844 | 206.861 | 109.25 | -16.044 | 80.628 |
Cash From Financing Activities | -7.325 | 245.933 | 308.423 | 306.965 | -7.577 |
Financing Cash Flow Items | -9.173 | -168.954 | -168.43 | -167.966 | -15.337 |
Issuance (Retirement) of Stock, Net | 1.848 | 101.317 | 101.316 | 99.394 | 7.76 |
Foreign Exchange Effects | -0.154 | -0.111 | -0.043 | -0.022 | -0.126 |
Net Change in Cash | -326.678 | 471.527 | 235.289 | 167.455 | 16.491 |
Issuance (Retirement) of Debt, Net | 313.57 | 375.537 | 375.537 |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
Fidelity Management & Research Company LLC | Investment Advisor | 14.9052 | 21307519 | 16360 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.4574 | 13519789 | 736550 | 2022-12-31 | LOW |
T. Rowe Price Investment Management, Inc. | Investment Advisor | 8.1692 | 11678259 | 521564 | 2022-12-31 | MED |
Bellevue Asset Management AG | Investment Advisor | 6.8161 | 9743900 | 280500 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.986 | 7127720 | 135266 | 2022-12-31 | LOW |
ClearBridge Investments, LLC | Investment Advisor/Hedge Fund | 3.7954 | 5425642 | -348250 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.9511 | 4218729 | 457774 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.9049 | 4152607 | -508999 | 2022-12-31 | LOW |
Tweedy, Browne Company LLC | Investment Advisor | 2.4771 | 3541136 | 818148 | 2022-12-31 | LOW |
ARK Investment Management LLC | Investment Advisor | 1.8702 | 2673538 | -1039569 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.408 | 2012723 | 111580 | 2022-12-31 | LOW |
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 1.3946 | 1993600 | 1224700 | 2022-12-31 | LOW |
Camber Capital Management LP | Hedge Fund | 1.3466 | 1925000 | 0 | 2022-12-31 | MED |
First Trust Advisors L.P. | Investment Advisor | 1.2458 | 1780933 | -296327 | 2022-12-31 | LOW |
Macquarie Investment Management | Investment Advisor | 1.0435 | 1491687 | 657646 | 2022-12-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.907 | 1296647 | 465428 | 2022-12-31 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.8788 | 1256268 | 53922 | 2022-12-31 | LOW |
Deep Track Capital LP | Hedge Fund | 0.8435 | 1205773 | 1205773 | 2022-12-31 | MED |
Renaissance Technologies LLC | Hedge Fund | 0.8246 | 1178814 | 311100 | 2022-12-31 | HIGH |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.7966 | 1138714 | 15634 | 2022-12-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group500K+
Traders
92K+
Clientes activos mensualmente
$53M+
Volumen mensual de inversión
$30M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ionis Pharmaceuticals Company profile
Sobre Ionis Pharmaceuticals Inc
Isis Pharmaceuticals, Inc. esta encargado en descubrir y desarrollar terapias dirigidas al acido ribonucleico (ARN). La Compañía, usando su plataforma de descubrimiento de medicamentos, ha desarrollado una línea de medicamentos para pacientes con necesidades medicas insatisfechas. Los segmentos de la Compañía incluye Iones Core y Akcea Therapeutics. En el segmento de Ionis Core, la Compañía se dedica a explotar una plataforma de descubrimiento para generar una tubería de medicamentos para la Compañía y sus socios. El segmentos Akcea Therapeutics incluye las operaciones de la subsidiaria de la Compañía, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics se centra en el desarrollar y comercializar volanesorsen y otros etapa clínica para enfermedades cardio metabólicas graves causadas por trastornos lipídicos. La Compañía esta desarrollando volanesorsen para tratar dos graves y raras, genéticamente definidas, la quilmicronemia familiar (FCS) y la lipodistrofia parcial familiar (LPF). La Compañía ofrece SPINRAZA, un medicamento anti sentido Generación 2.0+.
- IndustriaBiotechnology / Medical Research
- Dirección2855 Gazelle Ct, CARLSBAD, CA, United States (USA)
- Empleados660
- CEOJoseph Loscalzo
Industry: | Biotechnology & Medical Research (NEC) |
2855 Gazelle Court
CARLSBAD
CALIFORNIA 92010
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com